• Yunhong Zhang, Qiang Guo, Xunqiang Yin, Xiaoxiao Zhu, Lin Zhao, Zhen Zhang, Ran Wei, Bin Wang, and Xia Li.
• School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences Laboratory for Molecular Immunology, Institute of Basic Medicine, Shandong Academy of Medical Sciences Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
• Medicine (Baltimore). 2018 Jun 1; 97 (26): e11276e11276.

BackgroundThe association of XPA rs1800975 polymorphism with breast cancers has been reported in several studies, but the results were conflicting. In order to analyze the association between XPA rs1800975 polymorphism and the risk of breast cancer, a meta-analysis was performed in the present study.MethodsThe literature search for relevant studies was conducted in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang Med Online databases. The odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs) were calculated using fixed-effect/random-effects models by the STATA 12.0 software. The sources of heterogeneity were analyzed by subgroup analysis.ResultsSix case-control studies involving 5069 subjects (2338 patients and 2731 healthy controls) were included in the present meta-analysis. In the pooled analysis, no obvious association was found between XPA rs1800975 polymorphism and the risk of breast cancer in all genetic models. However, in subgroup analysis based on ethnicity, XPA rs1800975 polymorphism was found to be related to decreased breast cancer risk in non-Asians in the recessive model (OR = 0.80, 95% CI = 0.64-1.00, P = .045). Moreover, source of control subgroup analysis demonstrated that XPA rs1800975 polymorphism might decrease the risk of breast cancer in population-based group in the recessive model (OR = 0.80, 95% CI = 0.64-1.00, P = .045).ConclusionXPA rs1800975 polymorphism may decrease the risk of breast cancer in both non-Asians and population-based patients. Large sample size and well-designed study is needed for further assessing the role of XPA polymorphism in breast cancer risk.

10 keywords...

hide…